Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the Mehran risk score

Jin Wi, Young Guk Ko, Dong Ho Shin, Jung Sun Kim, Byeong Keuk Kim, Donghoon Choi, Jong Won Ha, Myeong Ki Hong, Yangsoo Jang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Contrast-induced nephropathy (CIN) has been generally considered to be transient and associated with unfavorable clinical outcomes. Hypothesis: The aim of this study was to investigate whether Mehran risk score could predict CIN with persistent renal dysfunction and long-term clinical outcomes in acute myocardial infarction (AMI) patients undergoing percutaneous coronary intervention (PCI). Methods: We analyzed the clinical data of 1041 AMI patients. The primary end point was defined as major adverse cardiovascular and cerebrovascular event (MACCE) including death, reinfarction, target vessel revascularization, heart failure requiring hospital admission, and stroke. Patients were categorized into 4 groups according to risk scores: low (≤ 5, n = 596), moderate (6-10, n = 265), high (11-15, n = 111), and very high (≥16, n = 69). Results: Among the 148 patients (14.2%) who developed CIN, persistent renal dysfunction was observed in 68 patients. Presence in high- or very high-risk groups was the most important independent risk factor of CIN with persistent renal dysfunction (odds ratio: 3.35, 95 confidence interval [CI]: 1.89-5.92, P < 0.001). Furthermore, patients in higher-risk groups experienced significantly more MACCE and mortality 2 years after PCI. Using multivariate analysis, significant increase in the hazard ratio (HR) for MACCE was noted in moderate- (HR: 1.40, 95% CI: 0.97-2.03, P = 0.075), high- (HR 1.96, 95% CI: 1.22-3.15, P = 0.006), and very high-risk (HR 2.40, 95% CI: 1.36-4.21, p = 0.002) groups, compared with the low-risk group. The very high-risk group had approximately 6-fold increase in mortality over the low-risk group (HR: 6.22, 95% CI: 2.77-13.95, P < 0.001). Conclusions: Mehran risk score predicted CIN with persistent renal dysfunction and long-term clinical outcomes in patients with AMI. Drs. Jin Wi and Young-Guk Ko contributed equally to the preparation of the article. This study was supported partly by grants from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (No. A085012, A102064, and A110879); the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (No.A08 5136); Yonsei University (6-2009-0008); Korea Institute of Medicine; and the Cardiovascular Research Center, Seoul, Korea. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Original languageEnglish
Pages (from-to)46-53
Number of pages8
JournalClinical Cardiology
Volume36
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Myocardial Infarction
Kidney
Korea
Confidence Intervals
Republic of Korea
Percutaneous Coronary Intervention
Odds Ratio
Conflict of Interest
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
Mortality
Family Health
Organized Financing
Health
Multivariate Analysis
Heart Failure
Stroke
Technology
Delivery of Health Care
Research

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{647e1e39a4774fa2b8c6ea8a2ac77466,
title = "Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the Mehran risk score",
abstract = "Background: Contrast-induced nephropathy (CIN) has been generally considered to be transient and associated with unfavorable clinical outcomes. Hypothesis: The aim of this study was to investigate whether Mehran risk score could predict CIN with persistent renal dysfunction and long-term clinical outcomes in acute myocardial infarction (AMI) patients undergoing percutaneous coronary intervention (PCI). Methods: We analyzed the clinical data of 1041 AMI patients. The primary end point was defined as major adverse cardiovascular and cerebrovascular event (MACCE) including death, reinfarction, target vessel revascularization, heart failure requiring hospital admission, and stroke. Patients were categorized into 4 groups according to risk scores: low (≤ 5, n = 596), moderate (6-10, n = 265), high (11-15, n = 111), and very high (≥16, n = 69). Results: Among the 148 patients (14.2{\%}) who developed CIN, persistent renal dysfunction was observed in 68 patients. Presence in high- or very high-risk groups was the most important independent risk factor of CIN with persistent renal dysfunction (odds ratio: 3.35, 95 confidence interval [CI]: 1.89-5.92, P < 0.001). Furthermore, patients in higher-risk groups experienced significantly more MACCE and mortality 2 years after PCI. Using multivariate analysis, significant increase in the hazard ratio (HR) for MACCE was noted in moderate- (HR: 1.40, 95{\%} CI: 0.97-2.03, P = 0.075), high- (HR 1.96, 95{\%} CI: 1.22-3.15, P = 0.006), and very high-risk (HR 2.40, 95{\%} CI: 1.36-4.21, p = 0.002) groups, compared with the low-risk group. The very high-risk group had approximately 6-fold increase in mortality over the low-risk group (HR: 6.22, 95{\%} CI: 2.77-13.95, P < 0.001). Conclusions: Mehran risk score predicted CIN with persistent renal dysfunction and long-term clinical outcomes in patients with AMI. Drs. Jin Wi and Young-Guk Ko contributed equally to the preparation of the article. This study was supported partly by grants from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (No. A085012, A102064, and A110879); the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (No.A08 5136); Yonsei University (6-2009-0008); Korea Institute of Medicine; and the Cardiovascular Research Center, Seoul, Korea. The authors have no other funding, financial relationships, or conflicts of interest to disclose.",
author = "Jin Wi and Ko, {Young Guk} and Shin, {Dong Ho} and Kim, {Jung Sun} and Kim, {Byeong Keuk} and Donghoon Choi and Ha, {Jong Won} and Hong, {Myeong Ki} and Yangsoo Jang",
year = "2013",
month = "1",
day = "1",
doi = "10.1002/clc.22060",
language = "English",
volume = "36",
pages = "46--53",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the Mehran risk score. / Wi, Jin; Ko, Young Guk; Shin, Dong Ho; Kim, Jung Sun; Kim, Byeong Keuk; Choi, Donghoon; Ha, Jong Won; Hong, Myeong Ki; Jang, Yangsoo.

In: Clinical Cardiology, Vol. 36, No. 1, 01.01.2013, p. 46-53.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the Mehran risk score

AU - Wi, Jin

AU - Ko, Young Guk

AU - Shin, Dong Ho

AU - Kim, Jung Sun

AU - Kim, Byeong Keuk

AU - Choi, Donghoon

AU - Ha, Jong Won

AU - Hong, Myeong Ki

AU - Jang, Yangsoo

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Contrast-induced nephropathy (CIN) has been generally considered to be transient and associated with unfavorable clinical outcomes. Hypothesis: The aim of this study was to investigate whether Mehran risk score could predict CIN with persistent renal dysfunction and long-term clinical outcomes in acute myocardial infarction (AMI) patients undergoing percutaneous coronary intervention (PCI). Methods: We analyzed the clinical data of 1041 AMI patients. The primary end point was defined as major adverse cardiovascular and cerebrovascular event (MACCE) including death, reinfarction, target vessel revascularization, heart failure requiring hospital admission, and stroke. Patients were categorized into 4 groups according to risk scores: low (≤ 5, n = 596), moderate (6-10, n = 265), high (11-15, n = 111), and very high (≥16, n = 69). Results: Among the 148 patients (14.2%) who developed CIN, persistent renal dysfunction was observed in 68 patients. Presence in high- or very high-risk groups was the most important independent risk factor of CIN with persistent renal dysfunction (odds ratio: 3.35, 95 confidence interval [CI]: 1.89-5.92, P < 0.001). Furthermore, patients in higher-risk groups experienced significantly more MACCE and mortality 2 years after PCI. Using multivariate analysis, significant increase in the hazard ratio (HR) for MACCE was noted in moderate- (HR: 1.40, 95% CI: 0.97-2.03, P = 0.075), high- (HR 1.96, 95% CI: 1.22-3.15, P = 0.006), and very high-risk (HR 2.40, 95% CI: 1.36-4.21, p = 0.002) groups, compared with the low-risk group. The very high-risk group had approximately 6-fold increase in mortality over the low-risk group (HR: 6.22, 95% CI: 2.77-13.95, P < 0.001). Conclusions: Mehran risk score predicted CIN with persistent renal dysfunction and long-term clinical outcomes in patients with AMI. Drs. Jin Wi and Young-Guk Ko contributed equally to the preparation of the article. This study was supported partly by grants from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (No. A085012, A102064, and A110879); the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (No.A08 5136); Yonsei University (6-2009-0008); Korea Institute of Medicine; and the Cardiovascular Research Center, Seoul, Korea. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

AB - Background: Contrast-induced nephropathy (CIN) has been generally considered to be transient and associated with unfavorable clinical outcomes. Hypothesis: The aim of this study was to investigate whether Mehran risk score could predict CIN with persistent renal dysfunction and long-term clinical outcomes in acute myocardial infarction (AMI) patients undergoing percutaneous coronary intervention (PCI). Methods: We analyzed the clinical data of 1041 AMI patients. The primary end point was defined as major adverse cardiovascular and cerebrovascular event (MACCE) including death, reinfarction, target vessel revascularization, heart failure requiring hospital admission, and stroke. Patients were categorized into 4 groups according to risk scores: low (≤ 5, n = 596), moderate (6-10, n = 265), high (11-15, n = 111), and very high (≥16, n = 69). Results: Among the 148 patients (14.2%) who developed CIN, persistent renal dysfunction was observed in 68 patients. Presence in high- or very high-risk groups was the most important independent risk factor of CIN with persistent renal dysfunction (odds ratio: 3.35, 95 confidence interval [CI]: 1.89-5.92, P < 0.001). Furthermore, patients in higher-risk groups experienced significantly more MACCE and mortality 2 years after PCI. Using multivariate analysis, significant increase in the hazard ratio (HR) for MACCE was noted in moderate- (HR: 1.40, 95% CI: 0.97-2.03, P = 0.075), high- (HR 1.96, 95% CI: 1.22-3.15, P = 0.006), and very high-risk (HR 2.40, 95% CI: 1.36-4.21, p = 0.002) groups, compared with the low-risk group. The very high-risk group had approximately 6-fold increase in mortality over the low-risk group (HR: 6.22, 95% CI: 2.77-13.95, P < 0.001). Conclusions: Mehran risk score predicted CIN with persistent renal dysfunction and long-term clinical outcomes in patients with AMI. Drs. Jin Wi and Young-Guk Ko contributed equally to the preparation of the article. This study was supported partly by grants from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (No. A085012, A102064, and A110879); the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (No.A08 5136); Yonsei University (6-2009-0008); Korea Institute of Medicine; and the Cardiovascular Research Center, Seoul, Korea. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

UR - http://www.scopus.com/inward/record.url?scp=84872281125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872281125&partnerID=8YFLogxK

U2 - 10.1002/clc.22060

DO - 10.1002/clc.22060

M3 - Article

C2 - 23027701

AN - SCOPUS:84872281125

VL - 36

SP - 46

EP - 53

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 1

ER -